PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Negative revenue growth while CRVO stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-148.93%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-24.41%
Negative EBIT growth while CRVO is at 14.54%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.41%
Negative operating income growth while CRVO is at 14.54%. Joel Greenblatt would press for urgent turnaround measures.
-24.71%
Negative net income growth while CRVO stands at 71.52%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-23.33%
Negative EPS growth while CRVO is at 71.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-23.33%
Negative diluted EPS growth while CRVO is at 71.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.68%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
89.77%
OCF/share CAGR of 89.77% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
79.09%
3Y OCF/share CAGR of 79.09% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-5123.81%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
89.73%
Net income/share CAGR of 89.73% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
77.51%
3Y net income/share CAGR of 77.51% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
1605.51%
Equity/share CAGR of 1605.51% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-64.94%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
48.08%
Equity/share CAGR of 48.08% while CRVO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-26.37%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
15.04%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
33.15%
SG&A growth well above CRVO's 0.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.